Endava PLC (NYSE:DAVA) IPO
IPO
Final prospectus filed on Jul 27, 2018.
- Price range
- US$17.00 to US$19.00 an ADS
- ADSs offered
- 5,600,000 American depositary shares · 2,890,000 from the company and 2,710,000 from selling shareholders
- Offering size
- US$95.2 million to US$106.4 million · ADSs offered times the price range, worked out by 6ix
- Underwriters' option
- Up to 840,000 more ADSs
- Listing
- DAVA on the New York Stock Exchange · Approved to list
- Underwriters
- MORGAN STANLEY, CITIGROUP, CREDIT SUISSE, DEUTSCHE BANK SECURITIES, COWEN, WILLIAM BLAIR · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 8, 2018 |
| Filed publicly | Jun 29, 2018 |
| Amended twice | Newest Jul 23, 2018 |
| Shares registered with an exchange | Jul 24, 2018 |
| Declared effective by the SEC | Jul 26, 2018 |
| Final prospectus, with the price | Jul 27, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 27, 2018 |
| EFFECT · Notice that a registration is effective | Jul 26, 2018 |
| F-1MEF · Registration of more shares for the same offering | Jul 26, 2018 |
| CERT · Exchange's certificate of listing | Jul 24, 2018 |
| CORRESP · Letter to the SEC | Jul 24, 2018 |
| CORRESP · Letter to the SEC | Jul 24, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 24, 2018 |
| F-1/A · Registration statement, amended | Jul 23, 2018 |
| F-1/A · Registration statement, amended | Jul 16, 2018 |
| CORRESP · Letter to the SEC | Jul 3, 2018 |
| CORRESP · Letter to the SEC | Jun 29, 2018 |
| F-1 · Registration statement | Jun 29, 2018 |
| UPLOAD · Letter from the SEC | Jun 26, 2018 |
| DRS/A · Draft registration statement, amended | Jun 19, 2018 |
| DRSLTR · Letter to the SEC with a draft | May 25, 2018 |
| UPLOAD · Letter from the SEC | May 1, 2018 |
| DRS/A · Draft registration statement, amended | Apr 16, 2018 |
| DRSLTR · Letter to the SEC with a draft | Apr 13, 2018 |
| UPLOAD · Letter from the SEC | Apr 4, 2018 |
| DRS · Draft registration statement | Mar 8, 2018 |
From the cover of the amended prospectus (F-1/A) filed Jul 23, 2018